Clinical Trial Search

Phase 3 N=160 Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19

Covid19

Primary: Proportional Change in D-dimer Level From Baseline to Day 8, or Day of Discharge if Prior to Day 8 (Phase 2b) — 137; 41.4; 34.7 Percent change — p=0.4715

ARCA Biopharma, Inc. Results Feb 2023 46.8% serious AE View details

Phase 3 N=1,604 Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation

Trauma Injury

Primary: Number of Participants With Mortality From Any Cause — 201; 192 Participants

Bryan Cotton Results Feb 2023 10.4% serious AE View details

Phase 3 N=99 A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07

Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma

Primary: Overall Response Rate (ORR) — 76.7; 0 percentage of participants

SecuraBio Results Feb 2023 72.7% serious AE View details

Phase 3 N=122 Trial Comparing Impact of PENG Block on Quality of Recovery Compared to No-block for Primary Total Hip Arthroplasty

Total Hip Arthroplasty

Primary: Recovery After Total Hip Arthroplasty — 131.5; 103 score on a scale

University of Alabama at Birmingham Results Feb 2023 0.0% serious AE View details

Phase 3 N=400 Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)

Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9

Primary: Percentage of Participants Achieving Neutralizing Antibody Seroconversion to Poliovirus Types 1, 2, and 3 at 1 Month Post Dose 3 of IPV — 98.9; 100.0; 98.3; 99.5…

Merck Sharp & Dohme LLC Results Feb 2023 4.6% serious AE View details

Phase 3 N=163 Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis

Multiple Sclerosis

Primary: Number of Combined Unique Active Lesions — 0.0; 0.0 lesions

Biocad Results Feb 2023 1.2% serious AE View details

Phase 3 N=1,301 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms

Primary: Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population…

Hoffmann-La Roche Results Feb 2023 40.4% serious AE View details

Phase 3 N=235 Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Hepatocellular Carcinoma · Unresectable Hepatocellular Carcinoma

Primary: Progression-free Survival (PFS) — 9.3; 8.4 months — p=0.4

National Cancer Institute (NCI) Results Feb 2023 48.6% serious AE View details

Phase 3 N=55 Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)

Merkel Cell Carcinoma

Primary: Objective Response Rate (ORR) — 49.1 Percentage of participants

Merck Sharp & Dohme LLC Results Feb 2023 43.6% serious AE View details

Phase 3 N=31 Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB

Dystrophic Epidermolysis Bullosa · Recessive Dystrophic Epidermolysis Bullosa · Dominant Dystrophic Epidermolysis Bullosa

Primary: Primary Wound With Complete Wound Healing (100% Wound Closure) on Weeks 22 and 24 or Weeks 24 and 26 — 20.9; 6.7 number of wounds with complete healing — p=0.00192

Krystal Biotech, Inc. Results Feb 2023 9.7% serious AE View details

Phase 3 N=342 Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia

Pneumonia, Bacterial

Primary: Number of Patients With Clinical Success as Judged by the Investigator — 158; 145; 6; 8 Participants — p==0.499

R-Pharm Results Feb 2023 0.6% serious AE View details

Phase 3 N=200 A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

HER2-positive Early Breast Cancer

Primary: Serum Trough Concentration (Ctrough) of Pertuzumab During Cycle 7 (Pre-Dose Cycle 8) — 69.9; 74.6 micrograms per millilitre (μg/mL)

Hoffmann-La Roche Results Feb 2023 18.5% serious AE View details

Phase 3 N=20 The CASCADE HF Soft Launch and Calibration Phase I and II

Heart Failure

Primary: Attrition Rate — 1; 2 Participants

Endeavor Health Results Feb 2023 0.0% serious AE View details

Phase 3 N=676 A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder

Depressive Disorder, Major

Primary: Percentage of Participants With Remission as Assessed by the Montgomery-Asberg Depression Rating Scale (MADRS) Score at Week 8 — 27.1; 17.6 Percentage of participants…

Janssen-Cilag International NV Results Feb 2023 5.4% serious AE View details

Phase 3 N=757 A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above

Respiratory Syncytial Virus Infections

Primary: RSVPreF3 Specific Immunoglobin (Ig)G Antibody Concentrations Expressed as Group Geometric Mean Concentration (GMC) — 86039.9; 80518; 94260.9 ELISA Units/milliliter

GlaxoSmithKline Results Feb 2023 2.8% serious AE View details